A Simple, Safe, and Effective Method for Preparing Autologous Bio-Based Fibrin Glue for Ophthalmic Use
Luis Fernández-Vega-Cueto1,2, Mairobi Persinal-Medina2,3, Natalia Vázquez2,3
1Instituto Oftalmológico Fernández-Vega, Avenida Doctores Fernández-Vega, 33012 Oviedo, Spain.
Pharmaceutics
|November 11, 2022
Summary
This study developed autologous fibrin glue (FG) from human blood for ophthalmic surgery. Concentrated fibrinogen FGs showed strong adhesion and safety in preclinical trials, offering a viable alternative to commercial options.
Area of Science:
- Biomaterials Science
- Ophthalmology
- Surgical Innovation
Background:
- Autologous fibrin glue (FG) is valuable in surgery.
- Current methods may have limitations in availability or efficacy.
- Need for readily prepared, effective bio-based adhesives in ophthalmic procedures.
Purpose of the Study:
- To develop and evaluate an autologous bio-based fibrin glue (FG) for ophthalmic surgery.
- To assess the impact of fibrinogen concentration on FG adhesion strength and clinical performance.
- To compare the efficacy and safety of autologous FG with commercial FG in a preclinical model.
Main Methods:
- Preparation of autologous FGs with varying fibrinogen concentrations (FG1, FG2, FG3) from human blood.
- Testing of adhesion strength of prepared FGs.
- Evaluation of clinical safety and efficacy in rabbit conjunctival surgery models.
- Comparison with a commercial fibrin glue as a control.
Main Results:
- Adhesion strength increased with fibrinogen concentration, ranging from 1.49 kPa (FG1) to 3.14 kPa (FG3).
- FG1 demonstrated insufficient adhesion for autografting.
- FG2 and FG3 showed successful conjunctival autografting with adhesion comparable to commercial FG, but with reduced inflammation.
- Autologous FGs were prepared rapidly from small blood volumes.
Conclusions:
- Autologous fibrin glue can be prepared quickly on demand from human blood.
- Concentrated fibrinogen FGs exhibit robust adhesion properties suitable for ophthalmic surgery.
- The developed autologous FG is safe and effective in preclinical studies, presenting a promising alternative to commercial products with potentially lower inflammatory response.
